Arcellx, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Gaithersburg MD United States (2015)

Organization Overview

First Clinical Trial
2019
NCT04155749
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Arcellx, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

ciltacabtagene autoleucel (Carvykti) (2 trials)

Drugs in Phase 1 Trials (2)

arc-t (1 trial)

sprx002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3